{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-013583","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.348392+00:00","generated_at":"2026-06-16T23:07:39.012080+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Heron Therapeutics announces commercial leadership changes: Poyhonen, Mathews depart; Grillot appointed VP","bullets":["John Poyhonen ceases as President and Chief Commercial Officer effective April 30, 2023.","Michael Mathews ceases as SVP Commercial, Acute Care effective April 30, 2023.","Jason Grillot appointed VP Sales and Marketing, Acute Care effective April 24, 2023.","Grillot granted 350,000 stock options with 4-year vesting as material inducement.","CEO Craig Collard will oversee commercial organization after departures."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-013583","json":"https://secwatch.observer/filing/0000950170-23-013583.json","markdown":"https://secwatch.observer/filing/0000950170-23-013583.md","text":"https://secwatch.observer/filing/0000950170-23-013583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/hrtx-20230418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:07:39.012080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"774132fa05","claim":"Michael Mathews departed as Senior Vice President Commercial, Acute Care at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"Also effective April 30, 2023, Michael Mathews will cease to serve as the Senior Vice President Commercial, Acute Care of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease to serve"},{"label":"Role","value":"Senior Vice President Commercial, Acute Care"}],"fact_type":"executive_change"},{"claim_id":"99dddd3d57","claim":"Jason Grillot was appointed as Vice President, Sales and Marketing, Acute Care at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"Additionally, effective April 24, 2023, Jason Grillot will join the Company as Vice President, Sales and Marketing, Acute Care.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"join"},{"label":"Role","value":"Vice President, Sales and Marketing, Acute Care"}],"fact_type":"executive_change"},{"claim_id":"cd22116024","claim":"John Poyhonen departed as President and Chief Commercial Officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"Effective as of April 30, 2023, John Poyhonen will cease to serve as the President and Chief Commercial Officer of Heron Therapeutics, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023013583/0000950170-23-013583-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"cease to serve"},{"label":"Role","value":"President and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}